Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

Background: Sorafenib was the first systemic therapy approved for the treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival and treatment outcomes and guide HCC systemic therapy. Type 1 insulin-like...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Mohamed, Yehia I., Lee, Sunyoung, Xiao, Lianchun, Hassan, Manal M., Qayyum, Aliya, Hiatia, Rikita, Pestana, Roberto Carmagnani, Haque, Abedul, George, Bhawana, Rashid, Asif, Duda, Dan G., Elghazaly, Hesham, Wolff, Robert A., Morris, Jeffrey S., Yao, James, Amin, Hesham M., Kaseb, Ahmed O.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2021
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8057275/
https://ncbi.nlm.nih.gov/pubmed/33889299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27924
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados